Cardiovascular and pulmonary adverse events in patients treated with BCR‐ABL inhibitors: Data from the FDA Adverse Event Reporting System

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E66-E72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Designing highly reliable adverse‐event detection systems to predict subsequent claims

By  

JOURNAL OF HEALTHCARE RISK MANAGEMENT, Vol. 34, Iss. 4, 2015-04 ,pp. : 7-17

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy

By Kim M.H.   Lin J.   Hussein M.   Battleman D.  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 3037-3047

Informa Healthcare

Access to resources Recommend Favorite

Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression

By Mandel Micha   Betensky Rebecca A.  

Biostatistics, Vol. 9, Iss. 4, 2008-10 ,pp. : 750-764

Oxford University Press

Access to resources Recommend Favorite

Monitoring the Harm Associated with Use of Anticoagulants in Pediatric Populations Through Trigger-Based Automated Adverse-Event Detection

By Patregnani Jason T.   Spaeder Michael C.   Lemon Valere   Diab Yaser   Klugman Darren   Stockwell David C.  

Joint Commission Journal on Quality and Patient Safety, Vol. 41, Iss. 3, 2015-03 ,pp. : 108-114

Joint Commission Resources

Access to resources Recommend Favorite